Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15643365 | 0.93 | LPL (0.45) | LPLLIPGCA2MGLLPLK1 | |
| SCHEMBL20408084 | 0.89 | LPL (0.47) | LPLLIPGCA2MGLLPLK1 | |
| SCHEMBL142480 | 0.85 | LPL (0.62) | LPLLIPGCA2MGLLPLK1 | |
| SCHEMBL320046 | 0.84 | CA2 (0.54) | LPLLIPGCA2MGLLPLK1 | |
| SCHEMBL4663409 | 0.82 | ESR1 (0.59) | LPLLIPGCA2MGLLCYP3A4 | |
| SCHEMBL7468095 | 0.82 | ESR1 (0.59) | LPLLIPGCA2MGLLCYP3A4 | |
| SCHEMBL2355588 | 0.82 | CYP3A4 (0.50) | CYP3A4IDO1APPCYP1A2CYP2D6 | |
| SCHEMBL9839848 | 0.82 | LPL (0.59) | LPLLIPGCA2MGLLPLK1 | |
| SCHEMBL6510298 | 0.82 | CYP3A4 (0.50) | CYP3A4IDO1APPCYP1A2CYP2D6 | |
| SCHEMBL8451636 | 0.82 | MAOB (0.53) | LPLLIPGCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103119082-A | Sacrificial polymer compositions including polycarbonates having repeat units derived from stereospecific polycyclic 2,3-diol monomers | PROMERUS LLC | 2013-05-22 | — | — | CN | claimed |
| CN-117402106-B | Multidentate organic ligand containing triphenylamine-terpyridine structure, metal supermolecular polymer, polymer film and preparation method | 吉林大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4400526-A1 | POLYMER AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | LG Chem, Ltd. (KR) | 2024-07-17 | — | — | EP | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| CN-117402106-A | Multidentate organic ligand containing triphenylamine-terpyridine structure, metal supermolecular polymer, polymer film and preparation method | 吉林大学 | 2024-01-16 | — | — | CN | disclosed |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115872967-A | Preparation method of dicyclic carbonate containing benzene ring structure | 浙江众立合成材料科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-0727428-A1 | Novel silacyclohexane compounds, preparation thereof, liquid crystal compositions comprising the same, and liquid crystal devices comprising the compositions | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1996-08-21 | — | — | EP | disclosed |
| EP-0560382-B1 | Difluoroethylene compounds and liquid crystal compositions containing them | ASAHI GLASS CO LTD (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5516949-A | LOW VISCOSITY AND PHOTOSTABLE | ASAHI GLASS COMPANY LTD. (JP) | 1996-05-14 | — | — | US | disclosed |
| EP-0688752-A1 | Trifluoro-2-(trans-4-substituted cyclohexyl) ethylenes and process for their production | ASAHI GLASS COMPANY LTD. (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5419851-A | Difluoro-derivative compounds and liquid crystal compositions containing them | ASAHI GLASS COMPANY LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| US-5380461-A | Trans-dihalogenostilbene compounds and liquid crystal electro-optical devices using them | SEIMI CHEMICAL CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0628528-A1 | DIFLUORIDE DERIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | ASAHI GLASS COMPANY LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| EP-0560382-A1 | Difluoroethylene compounds and liquid crystal compositions containing them | ASAHI GLASS COMPANY LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-4405757-A | Macromolecular complexes of amidocarbonylic water-soluble polymers and square planar platinous and equivalent organometallics | HOWELL BOBBY A | 1983-09-20 | — | — | US | disclosed |
| US-4186153-A | Process for 1,2,4,5-tetrachlorobenzene | THE DOW CHEMICAL COMPANY (US) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | NR1H3, NR1H4, NR1H2 | LPL 3396/4885LIPG 4631/4885CA2 1844/4885 |
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | LPL 138/4885LIPG 22/4885CA2 3083/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | LPL 3157/4885LIPG 1914/4885CA2 2802/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | LPL 184/4885LIPG 23/4885CA2 3300/4885 |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | NISCH, COASY, KLK7 | LPL 2546/4885LIPG 1797/4885CA2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.